Acenocoumarol is a highly effective drug to be used as anticoagulant drug. Due to variation in anticoagulant action, monitoring of INR is needed to adjust the dosage.Various factors affect the dose requirement of Acenocoumarol like age, gender, weight, height, drug interactions and variations in the VKORC1 and CYP2C9 genes. So we planned to compare effect of sex and different age groups on INR in patients who are taking Acenocoumarol 2 mg after Mechanical heart valve. Cross sectional study. After ethics approvals and Patients who were satisfying the inclusion and exclusion criteria, were recruited after written informed consent either in English or Tamil. Age, sex and INR values of the participants were noted. Datas were statistically analysed. 56 patients were recruited into the study. In that 50% of patients were male and 50% patients were female.At 5% of significance there was difference between males and females with INR. Patients were divided into four categories based on age 19-41 years, 42-48 years, 49-52 years and 53 to 88 years. But at 5% of significance there was no difference between different age groups with INR. There was no correlation between different age groups and INR. Our study indicated there is significant difference in INR of Acenocoumarol between males and females. But there is no significant difference in INR of Acenocoumarol between different age groups. However there are various factors other than age and sex that can affect INR of Acenocoumarol, it has to be confirmed with larger samples. Key words: Acenocoumarol, Anticoagulant, Mechanical heart valve.

A rapid and precise Reverse Phase High Performance Liquid Chromatographic method has been developed for the validated of Escitalopram and Flupentixol, in its pure form as well as in tablet dosage form. Chromatography was carried out on a Symmetry C18 (4.6 x 150mm, 5μm) column using a mixture of Methanol: TEA pH 4.2 (40:60) as the mobile phase at a flow rate of 1.0ml/min, the detection was carried out at 272 nm. The retention time of the Escitalopram and Flupentixol was 2.781, 4.048 ±0.02min respectively. The method produce linear responses in the concentration range of 7.5-37.5μg/ml of Escitalopram and 5-25μg/ml of Flupentixol . The method precision for the determination of assay was below 2.0%RSD. The method is useful in the quality control of bulk and pharmaceutical formulations. Key words: Escitalopram Oxalate, Flupenthixol Hydrochloride, Stability indicating RP-HPLC Method.

Extended release formulations, make the drug available over extended time period administration. Extended release will decrease the side effects of the drug by preventing the fluctuation of therapeutic concentration of the drug in the body. As Incorporating the dose for 24hrs into one tablet or capsule from which the drug is released slowly. These formulations have the potential to improve the patient compliance, reduce the toxicity by slowing drug absorption, and minimize drug accumulation with chronic dosing. Having improvement in bioavailability of some drugs. Usage of the less total drug and reduce the dose frequency. The article provides information about the overview of the design of the extended release system and different types of extended release system. Key words: Extended release oral drug delivery system,Design,Therapeutic concentration.